weight regain and cardiometabolic effects after withdrawal of semaglutide semaglutide: The STEP 1 trial extension Semaglutide as a GLP-1 Agonist:

More serious adverse effects that require monitoring include: Pancreatitis (treatment should be discontinued immediately if suspected) Gallbladder disease (cholelithiasis and cholecystitis) Diabetic retinopathy complications (particularly with rapid HbA1c reduction in patients with pre-existing retinopathy) Acute kidney injury (secondary to dehydration from gastrointestinal side effects) Increased heart rate Hypoglycaemia (particularly when used with insulin or sulphonylureas) Understanding the expected side effect profile helps patients distinguish between typical medication responses and symptoms that may warrant further medical evaluation

Novel therapeutic strategies for Alzheimers disease targeting brain cholesterol homeostasis

Sea buckthorn and grape seed extracts provide additional antioxidant support while offering their own skin and health benefits

9) However, a recent study examined the prevalence of heterozygotes for SLC22A5 mutations in 324 patients with cardiomyopathy and demonstrated that heterozygosity for PCD is not more frequent in patients with unselected types of cardiomyopathy and is unlikely to be an important cause of cardiomyopathy